These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26859223)

  • 1. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
    Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
    Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B; Lesosky M; Ntsekhe M
    S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
    Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
    Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
    Yahia DH; Pereg D; Lishner M; Elis A
    Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute coronary syndromes: clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005.
    Abdallah M; Karrowni W; Shamseddeen W; Itani S; Kobeissi L; Ghazzal Z; Alam S; Dakik HA
    Clin Cardiol; 2010 Jan; 33(1):E6-E13. PubMed ID: 20014175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Harrison RW; Simon D; Miller AL; de Lemos JA; Peterson ED; Wang TY
    Am Heart J; 2016 Aug; 178():95-101. PubMed ID: 27502856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Trends in Adherence to Secondary Prevention Guidelines for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical Outcomes Assessment Program (COAP) Registry.
    Riley RF; Don CW; Aldea GS; Mokadam NA; Probstfield J; Maynard C; Goss JR
    J Am Heart Assoc; 2012 Aug; 1(5):e002733. PubMed ID: 26600570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome.
    Hao Y; Liu J; Liu J; Smith SC; Huo Y; Fonarow GC; Ma C; Ge J; Taubert KA; Morgan L; Guo Y; Zhang Q; Wang W; Zhao D;
    Am Heart J; 2016 Sep; 179():107-15. PubMed ID: 27595685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI.
    Zeymer U; James S; Berkenboom G; Mohacsi A; Iñiguez A; Coufal Z; Sartral M; Paget MA; Norrbacka K; Ferrieres J; Bakhai A;
    Eur J Prev Cardiol; 2013 Apr; 20(2):218-28. PubMed ID: 22345684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of quality performance measures for primary percutaneous coronary intervention: A report from a tertiary referral centre in Switzerland.
    Haas C; Fournier S; Iglesias JF; Trana C; Roguelov C; Locca D; Lauriers N; Muller O; Eeckhout E
    Eur Heart J Acute Cardiovasc Care; 2016 Oct; 5(6):435-442. PubMed ID: 26474842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription Rates of Guideline-Directed Medications Are Associated With In-Hospital Mortality Among Japanese Patients With Acute Myocardial Infarction: A Report From JROAD - DPC Study.
    Nakao K; Yasuda S; Nishimura K; Noguchi T; Nakai M; Miyamoto Y; Sumita Y; Shishido T; Anzai T; Ito H; Tsutsui H; Saito Y; Komuro I; Ogawa H
    J Am Heart Assoc; 2019 Apr; 8(7):e009692. PubMed ID: 30909774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge.
    Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O
    J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
    Zeymer U; Berkenboom G; Coufal Z; Belger M; Sartral M; Norrbacka K; Bakhai A;
    Int J Cardiol; 2013 Dec; 170(2):239-45. PubMed ID: 24225199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS; Bajorek BV
    J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.